Safety and Efficacy Study of Topical Ranpirnase to Treat Genital Warts (HPV)

NCT02535104 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Condylomata Acuminata
Papillomavirus Infections
Sexually Transmitted Diseases

Interventions

DRUG: Ranpirnase
DRUG: Vehicle

Sponsor

Tamir Biotechnology, Inc.